marked.bio

Company

Sapience Therapeutics

2 active trials that select patients by a biomarker on marked.bio, across 1 biomarker.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

ST316 1bevacizumab 1fruquintinib 1

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

Trials

2 of 2 trials shown

  1. A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

    Active, not recruiting Phase 1/2 Sapience Therapeutics Started 2020Primary completion 2026-12 NCT04478279

    ST101temozolomide

    Patients that have BRAF mutated disease should also have received one line of appropriate targeted therapy iii.

    BRAF V600EGlioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer

  2. A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors

    Active, not recruiting Phase 1 Sapience Therapeutics Started 2023Primary completion 2026-12 NCT05848739

    ST316FOLFIRIbevacizumab FDA EUfruquintinibtrifluridine/tipiracil

    Subjects with TNBC or OC with known BRCA mutations must have been previously treated with or intolerant to Food and Drug Administration (FDA…

    BRCA1/2 mutationColon Cancer, Metastatic Colon Cancer